The JAK2/STAT3 pathway inhibitor, AG490, suppresses the abnormal behavior of keloid fibroblasts in vitro

Zhou,Ying; Sun,Yuexin; Hou,Wenjun; Ma,Liwen; Tao,Yue; Li,Dan; Xu,Cui; Bao,Jun; Fan,Weixin

doi:10.3892/ijmm.2020.4592

The JAK2/STAT3 pathway inhibitor, AG490, suppresses the abnormal behavior of keloid fibroblasts in vitro

Authors:
- Ying Zhou
- Yuexin Sun
- Wenjun Hou
- Liwen Ma
- Yue Tao
- Dan Li
- Cui Xu
- Jun Bao
- Weixin Fan
View Affiliations

Affiliations: Department of Dermatology, Drum Tower Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China, Department of Dermatology, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, Jiangsu 210008, P.R. China, Department of Dermatology, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 29, 2020 https://doi.org/10.3892/ijmm.2020.4592
Pages: 191-200
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

AG490 is a selective inhibitor of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. The present study examined its effects on the abnormal behavior of human keloid fibroblasts (HKFs) and evaluated its potential use in the treatment of keloids. Human normal fibroblasts (HNFs) and HKFs were treated with increasing concentrations of AG490. The proliferation of HNFs and HKFs was inhibited by AG490 in both a time‑ and concentration‑dependent manner by increasing apoptosis and inducing G1 cell cycle arrest. The downregulation of cyclin D1 and connective tissue growth factor (CTGF) expression was associated with a decrease in STAT3 expression in response to AG490. The effects of AG490 on TGF‑β‑stimulated fibroblasts, including HNFs, HKFs and hypertrophic scar fibroblasts (HSFs) were also evaluated. The TGF‑β1‑stimulated excessive proliferation and CTGF production were markedly inhibited by the application of AG490 in the HNFs, HSFs and HKFs. In addition, the STAT3‑specific decoy oligodeoxynucleotides (SODNs) were transfected into HKFs. The invasive ability of the SODN‑transfected HKFs was determined and the expression of extracellular matrix components was quantified. Similarly, SODNs blocked the constitutive activation of STAT3. SODNs inhibited the invasion and progression of HKFs, possibly via the upregulation of the expression of tissue inhibitor of metalloproteinase‑2 (TIMP‑2), and the downregulation of the expression of matrix metalloproteinase‑2 (MMP‑2) and vascular endothelial growth factor (VEGF). On the whole, the findings of the present study demonstrate that STAT3‑specific elimination, such as the application of AG490 and decoy ODNs, may serve as promising therapeutic strategies for the treatment of keloids.

View Figures

View References

1	Shih B, Garside E, McGrouther DA and Bayat A: Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen. 18:139–153. 2010. View Article : Google Scholar
2	Cosman B, Crikelair GF, Ju DMC, Gaulin JC and Lattes R: The surgical treatment of keloids. Plast Reconstr Surg. 27:335–358. 1961. View Article : Google Scholar
3	Viera MH, Vivas AC and Berman B: Treatment of keloids and scars. Ethn Dermatology Princ Pract:. 159–172. 2013. View Article : Google Scholar
4	Tuan TL and Nichter LS: The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 4:19–24. 1998. View Article : Google Scholar : PubMed/NCBI
5	Ledon JA, Savas J, Franca K, Chacon A and Nouri K: Intralesional treatment for keloids and hypertrophic scars: A review. Dermatol Surg. 39:1745–1757. 2013. View Article : Google Scholar : PubMed/NCBI
6	Manca G, Pandolfi P, Gregorelli C, Cadossi M and de Terlizzi F: Treatment of keloids and hypertrophic scars with bleomycin and electroporation. Plast Reconstr Surg. 132:621e–630e. 2013. View Article : Google Scholar : PubMed/NCBI
7	Vincent AS, Phan TT, Mukhopadhyay A, Lim HY, Halliwell B and Wong KP: Human skin keloid fibroblasts display bioener-getics of cancer cells. J Invest Dermatol. 128:702–709. 2008. View Article : Google Scholar
8	Naitoh M, Hosokawa N, Kubota H, Tanaka T, Shirane H, Sawada M, Nishimura Y and Nagata K: Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun. 280:1316–1322. 2001. View Article : Google Scholar : PubMed/NCBI
9	Uitto J, Perejda AJ, Abergel RP, Chu ML and Ramirez F: Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci USA. 82:5935–5939. 1985. View Article : Google Scholar : PubMed/NCBI
10	Babu M, Diegelmann R and Oliver N: Keloid fibroblasts exhibit an altered response to TGF-beta. J Invest Dermatol. 99:650–655. 1992. View Article : Google Scholar : PubMed/NCBI
11	Banerjee K and Resat H: Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 138:2570–2578. 2016. View Article : Google Scholar :
12	Lim CP, Phan TT, Lim IJ and Cao X: Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene. 25:5416–5425. 2006. View Article : Google Scholar : PubMed/NCBI
13	Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F and Rahim F: STATs: An old story, yet mesmerizing. Cell J. 17:395–411. 2015.PubMed/NCBI
14	Schlessinger K and Levy DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 65:5828–5834. 2005. View Article : Google Scholar : PubMed/NCBI
15	Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:645–648. 1996. View Article : Google Scholar : PubMed/NCBI
16	An JY, Pang HG, Huang TQ, Song JN, Li DD, Zhao YL and Ma XD: AG490 ameliorates early brain injury via inhibition of JAK2/STAT3-mediated regulation of HMGB1 in subarachnoid hemorrhage. Exp Ther Med. 15:1330–1338. 2018.PubMed/NCBI
17	Xu MY, Hu JJ, Shen J, Wang ML, Zhang QQ, Qu Y and Lu LG: Stat3 signaling activation crosslinking of TGF-β1 in hepatic stel-late cell exacerbates liver injury and fibrosis. Biochim Biophys Acta. 1842:2237–2245. 2014. View Article : Google Scholar : PubMed/NCBI
18	Nielsen M, Kaltoft K, Nordahl M, Röpke C, Geisler C, Mustelin T, Dobson P, Svejgaard A and Odum N: Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA. 94:6764–6769. 1997. View Article : Google Scholar : PubMed/NCBI
19	Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, et al: Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 1:893–899. 2002.PubMed/NCBI
20	Samanta AK, Lin H, Sun T, Kantarjian H and Arlinghaus RB: Janus kinase 2: A critical target in chronic myelogenous leukemia. Cancer Res. 66:6468–6472. 2006. View Article : Google Scholar : PubMed/NCBI
21	Abe M, Funakoshi-Tago M, Tago K, Kamishimoto J, Aizu-Yokota E, Sonoda Y and Kasahara T: The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int Immunopharmacol. 9:870–877. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ma J, Yan X, Lin Y and Tan Q: Hepatocyte growth factor secreted from human adipose-derived stem cells inhibits fibrosis in hypertrophic scar fibroblasts. Curr Mol Med. Jan 5–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
23	Wu X, Bian D, Dou Y, Gong Z, Tan Q, Xia Y and Dai Y: Asiaticoside hinders the invasive growth of keloid fibroblasts through inhibition of the GDF-9/MAPK/Smad pathway. J Biochem Mol Toxicol. 31:2017. View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Dunkel Y, Ong A, Notani D, Mittal Y, Lam M, Mi X and Ghosh P: STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. J Biol Chem. 287:41667–41683. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wlodkowic D, Telford W, Skommer J and Darzynkiewicz Z: Apoptosis and beyond: Cytometry in studies of programmed cell death. Methods Cell Biol. 103:55–98. 2011. View Article : Google Scholar : PubMed/NCBI
27	Pakyari M, Farrokhi A, Maharlooei MK and Ghahary A: Critical role of transforming growth factor beta in different phases of wound healing. Adv Wound Care (New Rochelle). 2:215–224. 2013. View Article : Google Scholar
28	Hanagata N: CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomedicine. 12:515–531. 2017. View Article : Google Scholar : PubMed/NCBI
29	Tomita N, Ogihara T and Morishita R: Transcription factors as molecular targets: Molecular mechanisms of decoy ODN and their design. Curr Drug Targets. 4:603–608. 2003. View Article : Google Scholar : PubMed/NCBI
30	Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283. 2004. View Article : Google Scholar : PubMed/NCBI
31	Efron PA and Moldawer LL: Cytokines and wound healing: The role of cytokine and anticytokine therapy in the repair response. J Burn Care Rehabil. 25:149–160. 2004. View Article : Google Scholar : PubMed/NCBI
32	Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku H and Kawanami O: Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol. 127:98–105. 2007. View Article : Google Scholar
33	Gazit A, Osherov N, Posner I, Yaish P, Poradosu E, Gilon C and Levitzki A: Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem. 34:1896–1907. 1991. View Article : Google Scholar : PubMed/NCBI
34	Chin GS, Liu W, Steinbrech D, Hsu M, Levinson H and Longaker MT: Cellular signaling by tyrosine phosphorylation in keloid and normal human dermal fibroblasts. Plast Reconstr Surg. 106:1532–1540. 2000. View Article : Google Scholar : PubMed/NCBI
35	Lipson KE, Wong C, Teng Y and Spong S: CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 5(Suppl 1): S242012. View Article : Google Scholar : PubMed/NCBI
36	Jurzak M, Adamczyk K, Antończak P, Garncarczyk A, Kuśmierz D and Latocha M: Evaluation of genistein ability to modulate CTGF mRNA/protein expression, genes expression of TGFβ isoforms and expression of selected genes regulating cell cycle in keloid fibroblasts in vitro. Acta Pol Pharm. 71:972–986. 2014.
37	Biernacka A, Dobaczewski M and Frangogiannis NG: TGF-β signaling in fibrosis. Growth Factors. 29:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
38	Walton KL, Johnson KE and Harrison CA: Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 8:4612017. View Article : Google Scholar
39	Song R, Li G and Li S: Aspidin PB, a novel natural anti-fibrotic compound, inhibited fibrogenesis in TGF-β1-stimulated keloid fibroblasts via PI-3K/Akt and Smad signaling pathways. Chem Biol Interact. 238:66–73. 2015. View Article : Google Scholar : PubMed/NCBI
40	Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, et al: Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst. 109:2017. View Article : Google Scholar : PubMed/NCBI